摘要
目的探讨基质金属蛋白酶(MMP)-3基因多态性与胃癌新辅助化疗疗效的关系及其作用机制。方法 MMP-3基因型检测采用聚合酶链反应-限制性片段长度多态性分析。结果携带5A/5A基因型的10例胃癌患者均化疗无效,而在有效患者中只有1例携带该基因型,其分布在无效组(9.3%)和有效组(1.4%)中差异有统计学意义(P=0.03)。其OR值有统计学意义(OR=8.24,95%CI=1.03～177,P=0.022)。另外,5A/5A+5A/6A基因型频率在无效组和有效组中分布差异无统计学意义(χ2=2.13,P=0.14)。结论胃癌患者各MMP-3基因型的新辅助化疗的有效率不同,5A/5A基因型的胃癌患者新辅助化疗有效率明显低于5A/6A组和6A/6A组,MMP-3单核苷酸多态性可能对胃癌新辅助化疗患者的筛选有潜在的应用前景。
Objective To investigate the relationship between MMP-3 gene polymorphism and neoadjuvant chemotherapy of gastric and mechanism.Methods Use polymerase chain reaction-restriction fragment length polymorphise（PCR-RFLP） to detect the MMP-3 gene.Results All the 10 gastric cancer patients which carrying 5A/5A genotype with chemotherapy were invalid,only 1 case carrying 5A/5A genotype in effective patients.The distribution in the ineffective group（9.3%） and effective group（1.4%） has significantly difference（P=0.03）,its OR value has significantly difference（χ2=2.13,P=0.14）,In addition,the frequencies of 5A/5A＋5A/6A genotype has no significantly difference in the distribution of ineffective group and effective group（χ2=2.13,P=0.14）.Conclusion The effective of neoadjuvant chemotherapy were different,the efficiency of 5A/5A genotype group in neoadjuvant chemotherapy patients with gastric cancer was significantly lower than the of 5A/6A and 6A/6A group.
出处
《山西医药杂志（上半月）》
CAS
2011年第11期1062-1064,共3页
Shanxi Medical Journal
基金
辽宁省自然科学基金(20082055)
关键词
基质溶解素1
胃肿瘤
基因多态性
化疗
Stromelysin 1
Gastric stomach neoplasms
Gene polymorphism
Chemotherapy
